潰瘍性大腸炎に対する白血球除去療法(LCAP)の有効性(<特集>白血球系細胞除去療法の最近の展開)

概要

論文の詳細を見る
Several uncontrolled trials with plasmapheresis and lymphocyte apheresis by centrifugation have shown therapeutic effectiveness in inflammatory bowel disease. To improve the efficiency and complexity of leukocyte removal, several devices have been developed. Currently, other than the centrifugal method, two such devices are used in clinical practice in Japan for the treatment of inflammatory bowel disease. Leukocytapheresis (LCAP), one of the 2 devices, is performed with the Cellsorba system^[○!R] (Asahikasei Medical Co., Japan). It uses a filter consisting of nonwoven hollow fibers to trap leukocytes. Blood inlet and outlet are via suitable veins in the bilateral forearms of the patient, and the procedure could easily be performed at an outpatient basis. It will nonselectively remove about 13.0×10^9 leukocytes from the circulating blood of the patient during one session of treatmennt. The removal efficacy of leukocytes passing through the filter is close to 100%. Furthermore, it will remove about 5.2×10^<11> platelets. The possible mechanism of action and the results of the pilot studies in ulcerative colitis are reviewed in this manuscript.
日本アフェレシス学会の論文
2005-05-31